声辐射力脉冲成像技术定量预测肝硬化食管静脉曲张程度的临床价值

目的探讨声辐射力脉冲成像(ARFI)技术定量分析预测肝硬化门静脉高压食管静脉曲张程度的临床价值。方法选取2014年10月-2016年2月解放军第三〇二医院收治的肝硬化患者116例,应用ARFI技术分别对肝脏、脾脏的实时超声弹性进行测量,以胃镜为食管静脉曲张程度的诊断金标准,将患者分为无曲张组(EV0,n=16)、轻度曲张组(EV1,n=39)、中度曲张组(EV2,n=26)和重度曲张组(EV3,n=35)。采用受试者工作特征曲线分析肝脏、脾脏ARFI技术预测食管静脉曲张程度的临床诊断价值。计量资料多组间比较采用方差分析或Kruskal-Wallis H检验,进一步两两比较采用Mann-Whitney U检验;计数资料多组间比较采用χ~2检验。ARFI弹性测值与食管静脉曲张程度的相关性采用Spearman相关分析。结果肝硬化患者食管静脉曲张程度从EV0至EV3级的脾脏ARFI测值分别为(2.54±0.34)、(3.05±0.34)、(3.48±0.50)、(3.69±0.33)m/s,组间比较差异有统计学意义(χ~2=60.121,P0.001)。脾脏ARFI测值与食管静脉曲张分级呈正相关(r=0.713,P0.001)。脾脏ARFI测值诊断不同食管静脉曲张程度≥EV1、≥EV2、EV3的受试者工作特征曲线下面积分别为0.93、0.88、0.83。肝脏ARFI测值在不同食管静脉曲张程度组间差异无统计学意义(P=0.085),其与肝硬化食管静脉曲张程度亦无相关性(P=0.245)。结论脾脏ARFI弹性测值可较准确地无创定量预测肝硬化门静脉高压食管静脉曲张程度,具有潜在的临床应用前景。     

声辐射力脉冲弹性成像技术预测肝硬化食管静脉曲张破裂出血的临床价值

目的探讨声辐射力脉冲弹性成像(ARFI)技术在预测肝硬化食管静脉曲张破裂出血中的临床价值。方法回顾分析2014年10月-2017年5月于解放军总医院第五医学中心就诊的271例肝硬化患者资料,所有患者均应用ARFI技术对肝脏和脾脏的超声弹性进行检测,并根据有无食管静脉曲张破裂出血将患者分为出血组(n=56)和无出血组(n=215),比较两组间相关指标的差异并结合受试者工作特征曲线(ROC曲线)评估分析ARFI弹性测值对肝硬化食管静脉曲张破裂出血的诊断价值。正态分布的计量资料2组间比较采用t检验;非正态分布的计量资料2组间比较采用Mann-Whitney U检验;计数资料2组间比较采用χ2检验。结果肝硬化食管静脉曲张出血组及无出血组脾脏ARFI弹性测值分别为3.89(3.49~4.11)m/s和3.46(2.93~3.80)m/s,出血组显著高于无出血组(Z=-4.941,P<0.001);出血组及无出血组肝脏ARFI弹性值分别为2.08(1.57~2.74)m/s和1.98(1.49~2.70)m/s,两组间差异无统计学意义(Z=-1.025,P=0.305)。脾脏和肝脏ARFI弹性测值预测肝硬化食管静脉曲张破裂出血的ROC曲线下面积分别为0.714和0.544(P=0.0025),以3.71 m/s作为脾脏ARFI弹性测值预测食管静脉曲张出血发生的诊断界值,其敏感度为0.68,特异度0.69。结论脾脏ARFI弹性测值较肝脏弹性测值可更有效预测肝硬化食管静脉曲张破裂出血的风险,具有良好的临床应用前景。     

FibroScan、AAR、APRI、FIB-4及其联合应用对乙型肝炎患者肝纤维化程度诊断效价的意义

目的:评估FibroScan、AST/ALT(AAR)、AST/PLT(APRI)、FIB-4及其联合应用对乙型肝炎患者肝纤维化程度的诊断效价。方法:回顾性分析406例慢性乙型肝炎及乙肝肝硬化住院患者,收集所有患者的肝脏硬度(LS)、AAR、APRI及FIB-4指数,比较慢性乙型肝炎和乙肝肝硬化两组患者LS、AAR、APRI及FIB-4指数的差异性,采用ROC曲线评价4项肝纤维化诊断指标鉴别慢性乙型肝炎及乙肝肝硬化不同疾病阶段的能力,并分析LS、AAR、APRI、FIB-4对于肝纤维化程度的评价相关性。结果:LS、AAR、FIB-4指数对肝纤维化的诊断效价在慢性乙型肝炎组与乙肝肝硬化组间比较差异具有显著性意义(P0.001);ROC曲线分析显示,鉴别诊断慢性乙型肝炎及乙肝肝硬化的LS、AAR、APRI及FIB-4指数ROC曲线下面积分别为0.866,0.772、0.632、0.885;鉴别诊断代偿期与失代偿乙肝肝硬化的LS、AAR、APRI及FIB-4指数ROC曲线下面积分别为0.627、0.666、0.795、0.820;LS分别与AAR、APRI、FIB-4指数间的Pearson相关系数分别为0.313、0.265、0.156,具有显著性意义(P0.05)。结论:LS、AAR、APRI及FIB-4指数可作为临床诊断及鉴别诊断乙型肝炎相关肝硬化的艮好指标。     

APRI、AAR对肝硬化食管静脉曲张的诊断价值

目的探讨谷草转氨酶/血小板比值指数(APRI)和谷草转氨酶-谷丙转氨酶比值(AAR)预测肝硬化食管静脉曲张的价值。方法肝硬化患者89例,均接受胃镜检查及血生化检验,应用受试者工作曲线评估APRI、AAR预测肝硬化患者食管静脉曲张存在的能力。结果静脉曲张组APRI为2.60±2.54,无静脉曲张组为0.77±0.68,两组相比有统计学意义(P<0.001);静脉曲张组AAR为1.27±0.53,无静脉曲张组为1.12±0.48,两组相比无统计学意义(P>0.05)。APRI预测食管静脉曲张的曲线下面积为0.84(0.75-0.93),最佳诊断界点为0.93,敏感度76.3%,特异度76.7%。APRI对轻度、中度、重度组食管静脉曲张预测的曲线下面积为0.66(0.47-0.85)、0.84(0.71-0.96)、0.92(0.84-0.99),最佳诊断值分别为0.7、0.93、1.02,灵敏度分别为54.5%、76.2%、88.9%,特异度为56.7%、76.7%、86.7%。结论 APRI可较好的预测食管静脉曲张的存在,APRI高值可提示重度静脉曲张。对于APRI高于0.93的患者,有必要进行胃镜检查。     

应用瞬时弹性成像技术联合APRI和AAR指数评估慢性乙型肝炎患者肝纤维化临床价值研究

目的 探讨应用瞬时弹性成像技术联合天门冬氨酸氨基转移酶(AST)/血小板指数(APRI)和AST/丙氨酸氨基转移酶(ALT)比值(AAR)评估慢性乙型肝炎(CHB)患者肝纤维化的临床价值。方法 2017年5月～2018年5月我院收治的CHB患者118例,给予所有患者恩替卡韦治疗观察12个月,治疗前接受肝活检,使用法国爱科森公司生产的FibroScan-502型瞬时弹性扫描仪行肝脏硬度检测(LSM),应用受试者工作特征曲线(ROC)评价LSM、APRI和AAR诊断CHB患者大于或等于S2期(显著)肝纤维化的效能。结果 在本组118例CHB患者中,经肝组织病理学检查,诊断S_0～1期(无肝纤维化组)65例,S_2～4期(显著肝纤维化组)53例;显著肝纤维化组血清ALT、AST、APRI、AAR和LSM分别为(128.3±31.4)U/L、(133.7±41.9)U/L、(0.5±0.2)、(1.5±0.5)和(9.3±2.7)kPa,与无肝纤维化组比,差异显著【分别为(104.6±26.8)U/L、(93.4±40.2)U/L、(0.3±0.1)、(1.2±0.3)和(5.6±1.6)kPa,P<0.05】,而外周血血小板计数为(123.4±46.4)×10⁹/L,显著低于无肝纤维化组【(184.2±42.8)×10⁹/L,P<0.05】;分别以7.830(kPa)、0.350和1.310为截断点,应用LSM、APRI和AAR诊断CHB患者显著肝纤维化的AUC分别为0.867(95%CI:0.827～0.947)、0.774(95%CI:0.678～0.861)和0.687(95%CI:0.500～0.774),三项指标联合诊断AUC为0.945(95%CI:0.904～0.986),显著高于任何一项单独指标(P<0.05);65例无显著肝纤维化患者治疗前后LSM、APRI和AAR变化不显著(P>0.05),而53例显著肝纤维化患者在治疗12个月后LSM为(7.4±1.2)kPa,显著低于治疗前【(9.3±2.7)kPa,P<0.05】。结论 应用瞬时弹性成像技术联合APRI和AAR检测CHB患者显著肝纤维化有一定的临床价值,值得进一步观察和研究。     

FibroScan联合多种预测模型预测肝硬化患者食管静脉曲张程度应用价值探讨

目的 探讨应用FibroScan和其他指标评判肝硬化患者食管静脉曲张(EV)程度的临床价值。方法 142例肝硬化患者接受胃镜检查,了解食管胃底静脉曲张情况,使用FibroScan检测肝脏硬度值(LSM),计算天冬氨酸氨基转移酶/血小板比值指数(APRI)、基于 4 因子的纤维化指数(FIB- 4)和γ-谷氨酰转肽酶/血小板计数模型(GPR),绘制受试者工作特征曲线(ROC),并计算曲线下面积(AUROC),评价各指标评判EV的临床价值。结果 本组患者经胃镜检查,发现无EV组49例,有EV组93例(G1 28例,G2 30例,G3 35例);EV组LSM、APRI、FIB-4和GPR分别为(25.8±1.6)kPa、(1.5±0.1)、(5.3±0.3)和(0.9±0.1),均显著大于无EV组【分别为(15.2±1.5)kPa、(0.7±0.1)、(2.9±0.3)和(0.4±0.1),P<0.05】;严重EV组LSM、APRI、FIB-4和GPR也显著大于无EV或轻度EV组;LSM、APRI、FIB-4和GPR判断EV≥G2的截断点分别为19.20 kPa、1.9、4.9和0.5,其诊断的灵敏度和特异度分别为68.7%和96.7%、60.0%和89.80%、61.5%和91.80%,和60.0%和85.70%。结论 应用FibroScan、APRI、FIB-4和GPR等无创性指标可以预测肝硬化患者食管静脉曲张的存在,对不能行胃镜检查的患者可作为一种替代方法而做出判断。     

ARFI、Forns指数、FIB-4和APRI无创诊断慢性乙型病毒性肝炎肝纤维化的研究

目的声辐射力脉冲成像技术(ARFI)及血清学诊断模型(Forns指数、FIB-4、APRI)对慢性乙型病毒性肝炎肝纤维化评估的价值。方法 111例确诊为慢性乙型病毒性肝炎患者,根据肝组织活检病理分期结果分组:无明显肝纤维化组(S0、S1)40例,明显肝纤维化组(≥S2)48例、早期肝硬化组(S4)23例。每例患者同期进行ARFI、Forns指数、FIB-4、APRI的评估。比较无创诊断模型与肝脏病理的相关性,并根据受试者工作特征曲线(ROC)分析无创诊断模型对肝纤维化的诊断价值。结果ARFI、Forns指数、FIB-4、APRI 4种无创诊断方法与肝组织活检具有良好的一致性,其皮尔逊相关系数(Pearson correlation coefficient)分别为0.882、0.639、0.589、0.418。明显肝纤维化组(≥S2)及早期肝硬化组,ARFI的诊断价值均优于FIB-4(Z=2.882,P=0.004;Z=3.215,P=0.001)、APRI(Z=4.850,P0.001;Z=3.198,P=0.001)、Forns指数(Z=2.182,P=0.029;Z=2.798,P=0.005)。结论 ARFI对明显肝纤维化及早期肝硬化的诊断具有较高的价值,值得推广。     

FibroScan、APRI及二者联合对肝硬化食管胃底静脉曲张出血的预测

目的探讨瞬时弹性成像技术(Fibro Scan)、天冬氨酸氨基转移酶和血小板比率指数(aspartate aminotransferase-to-platelet ratio index,APRI)及其二者联合检测肝硬化患者合并食管胃底静脉曲张破裂出血风险的相关性和诊断预测价值.方法将210例病毒性肝炎肝炎后肝硬化患者根据2015年《肝硬化门静脉高压食管胃静脉曲张出血的防治指南》分为无、有出血组,分别为153、57例;搜集患者在1 wk内的Fibro Scan值[肝脏硬度值(liver stiffness measurement,L S M)]和A P R I值.组间比较采用t检验,利用受试者工作特征曲线(receiver operating characteristic curve,ROC)分析LSM、APRI、LSM+APRI对肝硬化患者出血风险的预测价值,并比较LSM、APRI及LSM+APRI的ROC曲线下面积(area under curve,AUC).结果有、无出血组的LSM值分别是28.49 k Pa±9.46 k Pa,22.87 k Pa±6.95 k Pa,APRI值分别是2.99±1.11,2.13±1.01,有明显的统计学意义.有无出血风险的LSM、APRI、LSM+APRI的AUC分别是0.669、0.727、0.722,表明APRI、LSM+APRI对食管胃底静脉曲张破裂出血具有良好的诊断效果.结论APRI及Fibro Scan联合APRI对肝硬化患者合并食管胃底静脉曲张破裂出血风险存在有效的预测价值.     

肝脾硬度联合血清腺苷脱氨酶对乙型肝炎肝硬化重度食管静脉曲张的预测价值分析

目的评价FibroTouch(FT)瞬时弹性成像技术测量肝脾硬度及其联合血清腺苷脱氨酶(ADA)对乙型肝炎肝硬化患者重度食管静脉曲张(EV)的预判价值。方法选取2017年12月—2020年6月在长沙市第一医院感染科就诊的120例乙型肝炎肝硬化患者的临床资料,FT测量肝脏硬度值(LSM)和脾脏硬度值(SSM),完善电子胃镜、血清ADA、Hb、PLT、Alb、ALT及AST检查,计算血清肝纤维化指标APRI、AAR及FIB-4。将研究对象根据胃镜下EV程度,分为重度EV组(n=58)和非重度(无或轻中度) EV组(n=62)。满足正态分布的计量资料2组间比较采用t检验,非正态性的计量资料2组间比较采用Mann-Whitney U检验,计数资料2组间比较采用χ2检验。采用Spearman秩相关检验分析LSM、SSM、ADA与重度EV的关系。采用受试者工作特征曲线(ROC曲线)分析LSM、SSM、ADA诊断重度EV的效能,计算敏感度及特异度,行二分类变量logistic回归,计算联合指标的ROC曲线下面积(AUC),AUC比较应用Z检验。结果 LSM、SSM与ADA在2组间比较差异均有统计学意义(P值均0.05)。LSM、SSM、ADA与重度EV之间均存在显著正相关,相关系数分别为0.686、0.743和0.723(P值均0.05)。LSM、SSM、ADA预判重度EV的最佳阈值分别为22.35 kPa、45.25 kPa和34.50 U/L,AUC分别为0.746、0.802和0.791,灵敏度分别为82.8%、75.9%和58.6%,特异度分别为65.6%、77.4%和90.2%。LSM+ADA、SSM+ADA、LSM+SSM+ADA联合预判重度EV的AUC分别为0.826、0.853和0.907(P值均0.05)。结论肝脾硬度联合血清ADA对重度EV具有较好的预判价值,能够为临床上拒绝行胃镜检查患者预测重度EV提供初步诊断依据。     

剪切波弹性成像技术联合多参数评估肝硬化患者食管静脉曲张价值研究*

目的 探讨应用剪切波弹性成像(SWE)技术联合多参数评估肝硬化患者并发食管静脉曲张(EV)的价值。方法 2018年3月～2021年3月我院收治的肝硬化患者89例,接受胃镜检查,了解EV发生情况,采用SWE技术检测脾脏杨氏模量最大值(Emax)和杨氏模量平均值(Emean),使用彩色多普勒超声检测肝脏门静脉直径(PVD)、脾脏厚径(ST)、脾脏长径(SD)和脾静脉直径(SVD),应用受试者工作特征曲线下面积(AUC)分析各参数诊断肝硬化患者并发EV的效能。结果 经胃镜检查发现,本组89例肝硬化患者并发EV者53例;EV组在Child-Pugh分级、白蛋白、凝血酶原时间国际标准化比值、血小板计数和有腹水的比率等方面与非EV组比,均存在显著性差异(P<0.05);EV组Emax和Emean分别为(55.9±10.5)kPa和(38.9±9.2)kPa,显著大于非EV组【分别为(45.2±7.3)kPa和(29.3±6.7)kPa,P<0.05】,PVD、ST、SD和SVD分别为(13.6±2.1)mm、(48.0±9.4)mm、(149.1±27.1)mm和(10.1±1.9)mm,均显著大于非EV组【分别为(11.5±1.8)mm、(36.9±8.7)mm、(119.8±24.9)mm和(7.8±1.7)mm,P<0.05】;分别以Emax、Emean、PVD、ST、SD和SVD为53.2 kPa、33.6 kPa、11.9 mm、43.8 mm、136.5 mm和8.9 mm为截断点,其诊断肝硬化并发EV的AUC分别为0.84、0.83、0.73、0.80、0.67和0.82,诊断的敏感度和特异度分别为66.0%和88.9%、75.5%和77.8%、79.3%和61.1%、77.4%和72.2%、58.5%和69.4%、77.4%和80.6%。结论 应用SWE技术测量脾脏Emax和Emean可用于肝硬化患者并发EV的诊断,对帮助判断病情,及时予以预防处理。     

The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease

OBJECTIVE: The ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT) is often greater than 2:1 in alcoholic hepatitis. The purpose of this study was to determine whether this ratio may be used to distinguish nonalcoholic steatohepatitis (NASH) from alcoholic liver disease. METHODS: Patients with NASH were matched with controls with alcoholic liver disease based on age, gender, and date of diagnosis. The diagnosis of alcoholic liver disease was based on exclusion of other causes and a significant history of alcohol consumption. The diagnosis of nonalcoholic steatohepatitis was based on exclusion of other causes of liver disease and a liver biopsy showing > 10% steatosis and inflammation. The two sided Student t test was used for statistical analysis. RESULTS: From 1990 to 1996, 70 patients with NASH were matched with 70 subjects with alcoholic liver disease. Patients with NASH had a mean AST to ALT ratio of 0.9 (range 0.3-2.8, median 0.7) and subjects with alcoholic liver disease a mean ratio of 2.6 (range 1.1-11.2, median 2.0). The mean AST levels were 66 U/L and 152 U/L, and the mean ALT levels 91 U/L and 70 U/L, in the nonalcoholic steatohepatitis and alcoholic liver disease groups, respectively. Although the absolute aminotransferase levels were significantly different in the two groups (p < 0.05), the greatest difference was observed in the AST to ALT ratio (p < 0.000001). Subset analysis of patients with NASH revealed mean AST to ALT ratios of 0.7, 0.9, and 1.4 for subjects with no fibrosis, mild fibrosis, or cirrhosis, respectively. The differences among these ratios were statistically significant (p < 0.05). CONCLUSIONS: The AST to ALT ratio appears to be a useful index for distinguishing nonalcoholic steatohepatitis from alcoholic liver disease. Although values < 1 suggest NASH, a ratio of > or = 2 is strongly suggestive of alcoholic liver disease.     

The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients

Liver biopsy is currently the gold standard for determining the stage of liver fibrosis. There are risks associated with liver biopsy; therefore, surrogate markers to predict the severity of disease would be useful. We studied 50 patients with HIV/hepatitis C co-infection who had liver biopsies and determined that no patient with an aspartate aminotransferase/platelet ratio index (APRI) of 0.6 or less had stage F3 or F4 disease. The APRI is useful for excluding advanced disease in this patient population.     

Serum γ-glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase activity in Iranian healthy blood donor men

AIM： To determine serum γ-glutamyltransferase （GGT）, alanine aminotransferase （ALT）, and aspartate aminotransferase （AST） activity, and to assess their correlation with demographic and clinical findings in healthy blood donors.
METHODS： This cross-sectional study was performed in 934 male blood donors, aged 18 to 68 years, who consecutively attended Tehran blood transfusion service in 2006. All participants were seronegative for HBV or HCV infections, non alcohol users, and all underwent a standard interview and anthropometric tests. Clinical and biochemical parameters including AST, ALT, and GGT activities were determined. Patients taking drugs known to cause hepatic fat deposition were excluded. For AST, ALT, and GGT variables, we used 33.33 and 66.66 percentiles, so that each of them was divided into three tertiles.
RESULTS： Mean AST, ALT, and GGT activities were 25.26 ± 12.58 U/L （normal range 5-35 U/L）, 33.13 ± 22.98 （normal range 5-35 U/L）, and 25.11±18.32 （normal range 6-37 U/L）, respectively. By univariate analyses, there were significant associations between increasing AST, ALT, or GGT tertiles and age, body weight, body mass index, and waist and hip circumferences （P 〈 0.05）. By multiple linear regression analyses, ALT was found to be positively correlated with dyslipidemia （B = 6.988, P = 0.038）, whereas ALT and AST were negatively correlated with age. AST, ALT, and GGT levels had positive correlation with family history of liver disease （B = 15.763, P 〈 0.001）, （B = 32.345, P 〈 0.001）, （B =24.415, P 〈 0.001）, respectively.
CONCLUSION： Although we did not determine the cutoffs of the upper normal limits for AST, ALT, and GGT levels, we would suggest screening asymptomatic patients with dyslipidemia and also subjects with a family history of liver disease.     

Serum γ-glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase activity in Iranian healthy blood donor men

AIM: To determine serum γ-glutamyltransferase (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) activity, and to assess their correlation with demographic and clinical findings in healthy blood donors.METHODS: This cross-sectional study was performed in 934 male blood donors, aged 18 to 68 years, who consecutively attended Tehran blood transfusion service in 2006. All participants were seronegative for HBV or HCV infections, non alcohol users, and all underwent a standard interview and anthropometric tests. Clinical and biochemical parameters including AST, ALT, and GGT activities were determined. Patients taking drugs known to cause hepatic fat deposition were excluded. For AST, ALT, and GGT variables, we used 33.33 and 66.66 percentiles, so that each of them was divided into three tertiles.RESULTS: Mean AST, ALT, and GGT activities were 25.26 ± 12.58 U/L (normal range 5-35 U/L), 33.13 ± 22.98 (normal range 5-35 U/L), and 25.11 ± 18.32 (normal range 6-37 U/L), respectively. By univariate analyses, there were significant associations between increasing AST, ALT, or GGT tertiles and age, body weight, body mass index, and waist and hip circumferences (P < 0.05). By multiple linear regression analyses, ALT was found to be positively correlated with dyslipidemia (B = 6.988, P = 0.038), whereas ALT and AST were negatively correlated with age. AST, ALT, and GGT levels had positive correlation with family history of liver disease (B = 15.763, P < 0.001), (B = 32.345, P < 0.001), (B =24.415, P < 0.001), respectively.CONCLUSION: Although we did not determine the cutoffs of the upper normal limits for AST, ALT, and GGT levels, we would suggest screening asymptomatic patients with dyslipidemia and also subjects with a family history of liver disease.     

Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis

Background

Hepatic venous pressure gradient (HVPG) is the best recommended tool to measure portal pressure, but is invasive. HVPG helps in prognosticating cirrhosis and predict its complications. Aminotransferase to platelet ratio index (APRI) is a simple non-invasive marker of hepatic fibrosis. We aimed to correlate APRI with HVPG and to determine the usefulness of APRI in predicting complication of cirrhosis.

Methods

APRI and HVPG were measured in consecutive patients of cirrhosis aged 18 to 70 years. Spearman’s rho was used to estimate their correlation; a cut-off value of APRI to predict severe portal hypertension (HVPG >?12 mmHg) was determined.

Results

This study, conducted between August 2011 and December 2014, included 277 patients, median age 51 (range: 16–90) years, 84% males. Etiology of cirrhosis was alcohol in 135 (49%), cryptogenic/nonalcoholic steatohepatitis (NASH) in 104 (38%), viral in 34 (12%), and others in 4 (1%). Median Child-Turcott-Pugh (CTP) and model for end-stage liver disease (MELD) scores were 7 (5–11) and 11 (6–33), respectively. Median HVPG was 17.0 (1.5–33) mmHg and median APRI was 1.09 (0.21–12.22). There was positive correlation between APRI and HVPG (Spearman’s rho 0.450, p?<?0.001). The area under the receiver operating characteristic (ROC) curve of APRI for predicting severe portal hypertension was 0.763 (p?<?0.01). Youden’s index defined the cut-off of APRI for predicting HVPG >?12 mmHg was 0.876 with a sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of 71%, 78%, 94%, 38%, and 73%, respectively. APRI also correlated well with CTP, variceal size, bleeding status, ascites but not with MELD.

Conclusions

APRI score of 0.876 has an acceptable accuracy to predict severe portal hypertension (HVPG >?12 mmHg). High APRI also correlated with severity of cirrhosis and its complications. Thus, APRI may be used as a simple, bedside, non-invasive, and inexpensive tool for evaluating portal hypertension and complications of cirrhosis.

     

Isoenzymes of aspartate aminotransferase in chronic liver diseases

The total activity and activity of the cytoplasmic and mitochondrial isoenzyme of aspartate aminotransferase was examined in blood plasma of 56 patients with chronic liver diseases (chronic hepatitis in 27, liver cirrhosis in 23, secondary neoplastic effection of the liver in 6). All the patients with biochemically active forms of liver disease manifested increased the total as well as cytoplasmic enzyme activity, as compared with control group, 57% of the patients manifested simultaneously also increased activity of the mitochondrial isoenzyme. In 13% of the patients with stabilised forms of liver diseases manifested isolated increase of the mitochondrial isoenzyme activity. This might be of importance for the evaluation of the course of the disease. In patients with tumorous metastases in the liver a strikingly high share and activity of mitochondrial isoenzyme was shown.     

慢性乙型肝炎患者肝纤维化分级中AST/PLT比值指数的临床研究

目的评价天门冬氨酸氨基转移酶(AST)与血小板(PLT)比值在预测慢性乙型肝炎(CHB)肝纤维化分级中的作用。方法将178例CHB合并肝纤维化患者肝组织纤维化程度进行Ishak分期,同时检测患者AST和PLT,计算AST与PLT比值指数(APRI)。比较患者不同肝纤维化分期与APRI间的关系,通过APRI的受试者工作特征(ROC)曲线下面积,分析其预测显著肝纤维化及肝硬化的准确率,并对CHB肝纤维化患者抗病毒治疗前后肝组织纤维化分期和APRI的变化进行对比分析。结果 APRI与肝纤维化程度呈正比(P=0.001),APRI预测CHB进展为显著肝纤维化ROC曲线下面积为0.795,而预测肝硬化的ROC曲线下面积为0.714(P=0.003),APRI1.5和2分别为显著肝纤维化和肝硬化的截断点,其阳性预测值分别为96%和75%,阴性预测值分别为44%和74%。CHB患者经抗病毒药物治疗后,肝组织学检查结果显示其纤维化程度比治疗前明显减轻,而APRI也明显降低。结论 APRI可作为预测CHB患者发生显著肝纤维化及肝硬化的指标之一。